Cash received from option exercises
Vertex Pharmaceuticals Cash received from option exercises remained flat by 0.0% to $13.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.2%, from $12.50M to $13.90M. Over 2 years (FY 2023 to FY 2025), Cash received from option exercises shows a downward trend with a -17.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher proceeds indicate increased employee participation in equity programs and provide a minor source of liquidity for the company.
Detailed definition
The total cash proceeds received by the company from employees exercising their stock options. This represents a cash in...
Peer comparison
Standard cash flow statement line item for companies with active employee stock option plans.
other_proceeds_from_stock_options_exercisedHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $80.80M | $50.00M | $55.60M |
| YoY Change | — | -38.1% | +11.2% |
Cash received from option exercises at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's cash received from option exercises?
- Vertex Pharmaceuticals (VRTX) reported cash received from option exercises of $13.90M in Q4 2025.
- How has Vertex Pharmaceuticals's cash received from option exercises changed year-over-year?
- Vertex Pharmaceuticals's cash received from option exercises increased by 11.2% year-over-year, from $12.50M to $13.90M.
- What is the long-term trend for Vertex Pharmaceuticals's cash received from option exercises?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's cash received from option exercises has grown at a -17.0% compound annual growth rate (CAGR), from $80.80M to $55.60M.
- What does cash received from option exercises mean?
- Cash received by the company from employee stock option exercises.